Furthermore, Hyper-methylated In Cancer 1 (HIC1) in cancers can not only predict the prognosis (including lung cancer) but also predict the effects of immunotherapy and drug sensitivity, marking HIC1 as a potential biomarker with immune activity (82). Here, HIC1 is linked to lung cancer.